SGMO
$9.41
Sangamo Therapeutics
($.04)
(.42%)
SGMO
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  ($0.30)
Revenue:  $19.27 Mil
Wednesday
Feb 5
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when SGMO reports earnings?
Beat
Meet
Miss

Where is SGMO's stock price going from here?
Up
Flat
Down
Stock chart of SGMO
Analysts
Summary of analysts' recommendations for SGMO
Score
Grade
Pivots
Resistance
$9.68
$9.60
$9.51

$9.43

Support
$9.34
$9.26
$9.17
Tweet
Growth
Description
Sangamo BioSciences, Inc. is a leader in the development of novel transcription factors for the regulation of gene expression. Transcription factors are proteins that turn genes on or off by recognizing specific DNA sequences. The Universal Gene Recognition technology platform enables the engineering of a class of transcription factors known as zinc finger DNA binding proteins.
Peers
BiogenGilead SciencesAmgenBluebird BioNeurocrine BiosciencesSeattle GeneticsQiagen N.V.RepligenBioCryst PharmaceuticalsNovavax